Ipamorelin (5mg)

Research Overview

A selective growth hormone secretagogue that stimulates GH release via the ghrelin/GHSR-1a receptor without significantly affecting cortisol, ACTH, or prolactin levels. This selectivity distinguishes it from other GHRPs like GHRP-6 and hexarelin.

Origin: Synthetic pentapeptide GH secretagogue developed by Novo Nordisk

Mechanism of Action

• GHSR-1a (ghrelin receptor) agonism

• Selective GH pulse amplification

• Minimal cortisol/prolactin elevation

• No appetite stimulation (unlike GHRP-6)

• Synergy with GHRH analogs

Primary Research Areas

• GH secretion

• Body composition

• Bone density

• Age-related GH decline

• Selective secretagogue research

Key Published Findings

• Stimulated GH release comparable to GHRP-6 without cortisol or prolactin elevation

• Demonstrated dose-dependent GH release with a wider therapeutic window

• Synergistic GH amplification when combined with CJC-1295

Research Protocol

Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

-20°C lyophilized, 2-8°C reconstituted

Important Notice

Ipamorelin (5mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.